Cross N.C.P.; Ernst T.; Branford S.; Cayuela J.-M.; Deininger M.; Fabarius A.; Kim D.D.H.; Machova Polakova K.; Radich J.P.; Hehlmann R.; Hochhaus A.; Apperley J.F.; Soverini S., European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia, «LEUKEMIA», 2023, 37, pp. 2150 - 2167 [Scientific article]
Iezza M.; Cortesi S.; Ottaviani E.; Mancini M.; Venturi C.; Monaldi C.; De Santis S.; Testoni N.; Soverini S.; Rosti G.; Cavo M.; Castagnetti F., Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights, «CELLS», 2023, 12, Article number: 1703 , pp. 1703 - 1727 [Scientific article]Open Access
Soverini S., Resistance mutations in CML and how we approach them, in: Hematology, ASH Education Program, 2023, 2023, pp. 469 - 475 (atti di: 65th ASH Annual Meeting, San Diego, 9-12/12/2023) [Contribution to conference proceedings]
Mancini M.; Monaldi C.; De Santis S.; Papayannidis C.; Rondoni M.; Sartor C.; Bruno S.; Pagano L.; Criscuolo M.; Zanotti R.; Bonifacio M.; Tosi P.; Arock M.; Valent P.; Cavo M.; Soverini S., SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted, «BIOMARKER RESEARCH», 2023, 11, Article number: 29 , pp. 29 - 41 [Scientific article]Open Access
Bruno S.; Ghelli Luserna di Rora A.; Napolitano R.; Soverini S.; Martinelli G.; Simonetti G., CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies, «JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH», 2022, 41, Article number: 159 , pp. 1 - 16 [Scientific article]Open Access
de Santis S.; Monaldi C.; Martelli M.; Mancini M.; Bruno S.; Castagnetti F.; Gugliotta G.; Polakova K.M.; Ernst T.; Maar D.; Corner A.; Cavo M.; Soverini S., CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2022, 22, pp. 289 - 290 [Scientific article]
Mancini M.; Monaldi C.; De Santis S.; Rondoni M.; Papayannidis C.; Sartor C.; Curti A.; Bruno S.; Cavo M.; Soverini S., Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells, «CANCERS», 2022, 14, pp. 738 - 750 [Scientific article]Open Access
Soverini S.; De Santis S.; Martelli M.; Monaldi C.; Castagnetti F.; Gugliotta G.; Papayannidis C.; Mancini M.; Bruno S.; Venturi C.; Machova Polakova K.; Ernst T.; Maar D.; Corner A.; Cavo M., Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia, «LEUKEMIA», 2022, 36, pp. 2250 - 2260 [Scientific article]
Monaldi C.; de Santis S.; Mancini M.; Papayannidis C.; Sartor C.; Rondoni M.; Bruno S.; Cavo M.; Soverini S., MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2022, 22, pp. S328 - S328 [Scientific article]
De Santis S.; Monaldi C.; Mancini M.; Bruno S.; Cavo M.; Soverini S., Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia, «ONCOTARGETS AND THERAPY», 2022, 15, pp. 103 - 116 [Scientific article]Open Access
Mancini M.; De Santis S.; Monaldi C.; Castagnetti F.; Lonetti A.; Bruno S.; Dan E.; Sinigaglia B.; Rosti G.; Cavo M.; Gugliotta G.; Soverini S., Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors, «FRONTIERS IN ONCOLOGY», 2022, 12, Article number: 901132 , pp. 1 - 13 [Scientific article]Open Access
Baccarani M.; Bonifazi F.; Soverini S.; Castagnetti F.; Gugliotta G.; Saber W.; Estrada-Merly N.; Rosti G.; Gale R.P., Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia, «LEUKEMIA», 2022, 36, pp. 1227 - 1236 [Scientific article]Open Access
Gugliotta G.; Castagnetti F.; Breccia M.; Levato L.; Intermesoli T.; D'Adda M.; Salvucci M.; Stagno F.; Rege-Cambrin G.; Tiribelli M.; Martino B.; Bocchia M.; Cedrone M.; Trabacchi E.; Cavazzini F.; Porretto F.; Sora F.; Simula M.P.; Albano F.; Soverini S.; Foa R.; Pane F.; Cavo M.; Saglio G.; Baccarani M.; Rosti G., Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study, «HAEMATOLOGICA», 2022, 107, pp. 2356 - 2364 [Scientific article]Open Access
Schafer V.; White H.E.; Gerrard G.; Mobius S.; Saussele S.; Franke G.-N.; Mahon F.-X.; Talmaci R.; Colomer D.; Soverini S.; Machova Polakova K.; Cross N.C.P.; Hochhaus A.; Ernst T., Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2021, 147, pp. 3081 - 3089 [Scientific article]Open Access
Soverini S.; Martelli M.; Bavaro L.; De Benedittis C.; Sica S.; Sora F.; Iurlo A.; Bonifacio M.; Pregno P.; Galimberti S.; Lunghi F.; Albano F.; D'Adda M.; Crugnola M.; Capodanno I.; Castagnetti F.; Gugliotta G.; Papayannidis C.; Rosti G.; Percesepe A.; Mignone F.; Baccarani M.; Martinelli G.; Cavo M., BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS, «LEUKEMIA», 2021, 35, pp. 2102 - 2107 [Scientific article]
